RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated <i>EGFR</i>-Mutated Metastatic NSCLC.

18 Although median OS was not reached in both treatment groups, a favorable trend for amivantamab plus lazertinib was observed in the Asian population (median follow-up: 22.5 months; HR 0.84; 95% CI: 0.58‒1.23; nominal p = 0.380). 33 Moreover, both of these studies included patients with asymptomatic or stable CNS metastases.

also in 1,335 other papers

13 , 14 Conversely, in the global RELAY population, a positive trend in median OS was observed with RAM plus erlotinib versus placebo plus erlotinib for patients with L858R (51.6 versus 45.8 mo; HR 0.87; 95% CI: 0.62‒1.22), but not for those with ex19del (49.0 versus 51.4 mo; HR 1.13; 95% CI: 0.83‒1.55). 20 Furthermore, the 3-year OS rate was higher with RAM plus er

also in 11,005 other papers